Stocksigma LogoStocksigma Logo

Ipca Laboratories Q2 FY'27 Earnings Call Summary

Ipca Laboratories reported 14% YoY consolidated revenue growth to INR2,910 crore in Q2 FY'27, with EBITDA margins expanding to 22.97% from 21.68%

Ipca Laboratories Q2 FY'27 Earnings Call Summary

Ipca Laboratories Ltd · Transcript · 06 Nov 2026, 11:01 pm

Ipca Laboratories Q2 FY'27 Earnings Call Summary Ipca Laboratories reported 14% YoY consolidated revenue growth to INR2,910 crore in Q2 FY'27, with EBITDA margins expanding to 22.97% from 21.68%. Domestic formulations grew 14% YoY to INR1,157 crore, driven by Zerodol umbrella sales surpassing INR1,500 crore. Standalone export formulations rose 32% YoY to INR653 crore, supported by strong generic demand across Europe, Canada, and South Africa. Management maintained FY'27 revenue growth guidance at 14–16% with EBITDA margins of 22–23%, aiming for 100–125 bps annual margin expansion. The balance sheet remains virtually debt-free with ~INR700 crore cash.

Original exchange filing (PDF)

More announcements from Ipca Laboratories Ltd

All Ipca Laboratories Ltd announcements